Extracellular vesicles
from adipose-derived MSCs
Extracellular vesicles (EVs) play an essential role in cellular communication by transporting proteins, lipids as well as nucleic acids. EVs from our adipose-derived mesenchymal stromal cell line ASC/TERT300 are characterized by the typical EV morphology, presence of EV marker proteins as well as anti-inflammatory and anti-fibrotic activities.
General information
Cat#: EV-001-0300-A2 (5 x 10^9 EVs in 50 µl buffer)
Presence of typical EV marker proteins
EVs derived from ASC/TERT300 cells carry typical surface proteins such as CD81, CD9 and CD63 as demonstrated by bead-based flow cytometry, using hCD81 positive isolation beads. Delta mean fluorescence intensity (DMFI) was calculated by normalizing to MFI of control beads.
Anti-inflammatory activity of extracellular vesicles from ASC/TERT300
Treatment of mouse macrophage cells (RAW264.7) with lipopolysaccharide (LPS) induces the formation of nitric oxide (NO) formation indicating an inflammatory reaction.
Anti-fibrotic activity of extracellular vesicles from ASC/TERT300
Treatment of human fibroblasts (fHDF/TERT166) with Transforming Growth Factor beta (TGF-ß1) induces the expression of alpha smooth muscle actin (α-SMA) indicating myofibroblast differentiation/activation, which is a key event in physiological and pathological tissue repair.
Addition of EVs derived from ASC/TERT300 cells significantly reduces α-SMA induction, indicating an anti-fibrotic activity of the EVs.
FAQs
Upon arrival immediately transfer the product to -80°C.
Store product at -80°C (for up to 6 months) until use.
Thaw the EVs on ice, centrifuge before opening the tube to ensure that the solution is collected at the bottom of the tube. Then, mix carefully by pipetting up and down and aliquot for further use to avoid multiple freeze thaw cycles.
Store the aliquots at -80°C until use.
After thawing, store the EVs at 4°C for a maximum of 1 day.
Product data sheet – certificate of analysis
Data on Markers and Functions
Applications
Selected publications: exosomes for the treatment of COVID-19
Sengupta V, Sengupta S, Lazo A, Woods P, Nolan A, Bremer N. (2020) Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19. Stem Cells Dev. 2020 Jun 15;29(12):747-754. https://pubmed.ncbi.nlm.nih.gov/32425691/
Selected publications: extracellular vesicles for the treatment of wounds
Casado-Díaz A, Quesada-Gómez JM, Dorado G. (2020) Extracellular Vesicles Derived From Mesenchymal Stem Cells (MSC) in Regenerative Medicine: Applications in Skin Wound Healing. Front Bioeng Biotechnol. 8:146. https://pubmed.ncbi.nlm.nih.gov/32195233/
Customer Reviews
“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”
Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.
“Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform. We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed.”
Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.
EV-BM-MSC/TERT292 (5 x 10^9 particles)
Customer Reviews
“I have had the pleasure of working with Evercyte for the last few years. We continually rely on Evercyte because of the high-quality data that they produce, their diligent responsiveness, and their excellent customer service.”
Josh Garlich, Senior Research Scientist, Apellis Pharmaceuticals, Inc.
“Cytonus has been working with Evercyte from many years as they are a trusted partner and have always delivered the highest quality cell lines to advance our platform. We routinely draw on their expertise to meet cellular engineering challenges and they have not disappointed.”
Remo Moomiaie-Qajar, Cytonus Therapeutics, Inc.